Smoking Cessation Support Tool

INITIAL DATA CAPTURE								
Client Details								
Does th	ne client consent to follow up?	☑ Yes						
CHI: First Name:					Surname:			
Date of	Birth: / /	Gender: 🗆	Male	Female	Title:			
Addres	S:		Home Tele	ephone:				
			Mobile Tel	ephone:			allow-UD	
			Work Tele	phone:	aquire	d for 1	follow-up	
Postcoo	de:		Email Add	ress	require			
If fema	lle, pregnant? 🛛 Yes 🗆	No						
	the clients ethnic group?							
White	□ Scottish □ Irish	🗆 Other Br	itish 🗆	l Polish 🛛 🗆 C)ther 🗌 🛛	Gypsy Trav	veller	
Asian	🗆 Asian Indian 🛛 Asian F	Pakistani	🗆 Asian Ba	angladeshi 🗆 As	sian Chinese	🗆 Asiar	o Other	
Black	🗆 Black African 🛛 Black	Caribbean	🗆 Black Ot	her 🛛 Other Af	rican		🗆 Arab	
Mixed (please specify):		Other (ple	ase specify):			□ Not Disclosed	
What is	the clients Employment Status	?	·					
	id employment 🛛 Unemp		Retired	Full Time Student	🗆 Permar	nently Sick	or Disabled	
	emaker/ Full time parent/ Care	5	(please spe	cify):			known/ Missing	
Tobacc	o use and quit attempts							
On ave	rage, how many cigarettes does	the client usua						
□ 10 o		□ 21-30		lore than 30	🗆 Unknowr	า		
How soon after waking up does the client usually smoke their first cigarette? Within 5 minutes G 6-30 minutes G 31-60 minutes After one hour Unknown								
How many times has the client tried to quit smoking in the past year?								
			unies		mes		WII	
	l and assessment context							
	eferred to Service:: / /_					Smokel		
Dent		ealthPoint		Pharmacist Prostice Nurse		ine		
□ Dent		ospital idwife		 Practice Nurse Stop Smoking Research 				
		cify)		Jaushow		ve scheme		
		her (please spe	,eny)					
Date of initial appointment://								
Intervention(s) used in this quit attempt) I One to one sessions								
Shared care between pharmacy and non-pharmacy services? Yes No Pharmaceutical usage (at week 0 may not yet be determined and can edited at week 1, but if varenicline to be used must select at								
week 0 so that risk assessment prompts appear)								
□ NRT only (single product) □ NRT and Buproprion (change in product)								
	□ NRT only (but more than one NRT product) □ NRT and Varenicline (change in product) □ Unknown							
□ Varenicline only □ Unknown □ None								
Total Number of weeks of known product use (likely to be 0)								
If varenicline to be supplied, a risk assessment must be completed prior to supply								
	ssessment indicate that the pati				viateness? 🗆	Yes 🗆 N		
	m that I am aware the GP must							
I COMIN						use follow	up/MDS prompts are	
Quit Da	ite//			•			confirmed – triggers	

CC	CONTACT RECORDS WEEKS 1-4							
	Date	Contact Type	Smoked?	CO	Product	Product/Contact Notes:		
1		 □ Face to Face □ Telephone □ Email 	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline			
2		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline			
3		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline			
4		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline			

4 WEEK MDS SUBMISSION								
Was client successfully contacted for 1-month follow up? Yes No Da	ate follow up carried out: /	_/	Client wit	hdrawn fro	m service at time of follow up?	🗆 Yes	□ No	
Has client smoked at all (even a puff) in the last 2 weeks?	CO read	ding confirms quit?	□ Yes	□ No	🗆 CO Not Taken			
Reason CO reading not taken? Patient declined Equipment not available	able 🛛 🗆 Follow up not in person							

CO	ONTACT RECORDS WEEKS 5-12					
	Date	Contact Type	Smoked?	CO	Product	Product/Contact Notes:
5		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline	
6		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline	
7		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline	
8		 □ Face to Face □ Telephone □ Email 	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline	
9		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline	
10		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline	
11		□ Face to Face □ Text □ Telephone □ Email	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline	
12		 □ Face to Face □ Telephone □ Email 	□ Yes □ No		□ 16 hr patch □ 24 hr patch □ Lozenge □ Sub-Lingual tablet □ Gum □ Nasal Spray □ Inhalator □ Varenicline	

12 WEEK MDS SUBMISSION									
Was client successfully contacted for 3-month follow up? Yes No	Date follow up carried out://	Has client smoked at all since 1 month follow up? \Box Yes \Box No							
CO reading confirms quit? Yes No CO Not Taken CO Not Taken	Reason CO reading not taken?	Equipment not available Follow up not in person							